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Individuals with chronic kidney disease (CKD) and periodontitis as a co-morbidity have a 31 
higher mortality rate than individuals with CKD and no periodontitis. The inflammatory 32 
burden associated with both diseases contributes to an increased risk of cardiovascular and 33 
all-cause mortality. We previously demonstrated that periodontitis is associated with 34 
increasing circulating markers of inflammation and oxidative stress. We propose that 35 
inflammatory oxidised phosphocholines may contribute to the increased risk of 36 
cardiovascular disease in patients with CKD. However, the analysis of oxidised phospholipids 37 
has been limited by a lack of authentic standards for absolute quantification. Here, we have 38 
developed a comprehensive quantification liquid chromatography-mass spectrometry-39 
based multiple reaction monitoring method for oxidised phospholipids (including some 40 
without available authentic species) that enables us to simultaneously measure twelve 41 
oxidised phosphocholine species with high levels of sensitivity and specificity. The standard 42 
curves for commercial standards 1-palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine 43 
(PGPC); 1-palmitoyl-2-(9'-oxo-nonanoyl)-sn-glycero-3-phosphocholine (PONPC), 1-palmitoyl-44 
2-azelaoyl-sn-glycero-3-phosphocholine (PAzPC) and 1-palmitoyl-2-(5'-oxo-valeroyl)-sn-45 
glycero-3-phosphocholine (POVPC), were linear with a correlation coefficient greater than 46 
0.99 for all analytes. The method is reproducible, with intra- and inter-day precision <15%, 47 
and accuracy within ±5% of nominal values for all analytes. This method has been 48 
successfully applied to investigate oxidised phosphocholine in plasma from CKD patients 49 
with and without chronic periodontitis and the data that was obtained has been compared 50 
to plasma from healthy controls. Comparative analysis demonstrates altered chain 51 
fragmented phosphocholine profiles in the plasma samples of patients with CKD and 52 
periodontitis as a co-morbidity compared to healthy controls.  53 
 54 













CV  Coefficient of variation 66 
CKD  Chronic kidney disease 67 
dDMPC 1, 2-dimyristoyl-sn-glycerol-3-phosphocholine-1,1,2,2-d4-N,N,N-trimethyl-d9 68 
MRM  Multiple reaction monitoring 69 
OxPC  Oxidized phosphocholine 70 
PAPC  1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphorylcholine 71 
PAzPC  1-palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine 72 
PGPC  1-palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine 73 
PL  Phospholipid 74 
PLPC  1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphocholine 75 
PONPC  1-palmitoyl-2-(9'-oxo-nonanoyl)-sn-glycero-3-phosphocholine 76 
POVPC  1-palmitoyl-2-(5'-oxo-valeroyl)-sn-glycero-3-phosphocholine 77 
PPD  Probing pocket depth 78 
QC  Quality control 79 
ROS  Reactive oxygen species 80 
SAPC  1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine 81 
SAzPC  1-stearoyl-2-azelaoyl-sn-glycero-3-phosphocholine 82 
SD  Standard deviation 83 
SE  Standard error 84 
SGPC  1-stearoyl-2-glutaryl-sn-glycero-3-phosphocholine 85 
SLPC  1-stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine 86 
SONPC  1-stearoyl -2-(9'-oxo-nonanoyl)-sn-glycero-3-phosphocholine 87 
SOVPC  1-stearoyl-2-(5'-oxo-valeroyl)-sn-glycero-3-phosphocholine 88 


















1. Introduction 105 
Chronic kidney disease (CKD) affects up to 16% of the population worldwide, increases in 106 
prevalence with age and is associated with high morbidity and mortality compared to 107 
individuals without CKD [1, 2].  Traditional risk factors for CKD such as age, gender, ethnicity, 108 
family history, smoking habits,  and socioeconomic status are also associated with diabetes, 109 
hypertension, and lipid disorder comorbidities; individually and collectively these contribute 110 
to a higher cardiovascular disease morbidity and mortality [3]. Non-traditional risk factors 111 
are also associated with poorer CKD outcomes,  including inflammation, which is strongly 112 
associated with an increased risk of progression to end-stage renal failure and mortality [1]. 113 
Identifying and targeting novel, modifiable risk factors that contribute to systemic 114 
inflammation in CKD and are causal for poorer clinical outcomes represents an effective 115 
strategy for reducing morbidity and mortality in those affected [4].  116 
Periodontitis is the most common chronic inflammatory disease of humans, affecting about 117 
40-50% of the global population and in its most severe form is the sixth most common 118 
human disease (11.2%)[5]. The global burden of periodontitis increased from 1990 to 2010 119 
by 57.3% [6]. Indeed, oral diseases, including periodontitis were the leading causes of non-120 
fatal health loss in males and females, determined by years lived with disability, in The 121 
Global Burden of Diseases, Injuries, and Risk Factors Study 2017 (GBD 2017). Periodontitis 122 
leads to significant elevations in both acute-phase reactants (CRP, IL-6) [5, 7] and oxidative 123 
stress biomarkers in plasma [8]. Our previous work demonstrated that CKD patients who are 124 
at high risk of progression to end-stage renal disease [9], had a significantly greater 125 
prevalence (88%) and severity of periodontitis compared to a local, community dwelling 126 
control population (55%) [10]. Using survival analysis carried out in the Third National 127 
Health and Nutrition Examination Survey (NHANES III) of the USA and linked mortality data, 128 
we demonstrated a strong association between periodontitis and increased mortality in 129 
individuals with CKD [10, 11]. Given the existing oxidative stress burden in periodontitis [8], 130 
others have analysed the plasma oxidation status of patients with CKD and found that the 131 
lipid peroxidation product F2-isoprostane was elevated [12].  132 
The unsaturated fatty acid chains present in sn-1 or sn-2 position of phospholipids (PLs) can 133 
undergo either enzymatic (e.g. by lipoxygenases) or non-enzymatic oxidation (by reactive 134 
oxygen species; ROS such as the hydroxyl radical, superoxide anion, peroxynitrite, 135 
hypochlorite anion and peroxide) to yield oxidised phospholipids (oxPLs) and after release 136 
by phospholipases, to form isoprostane species. Oxidative modifications include oxidation of 137 
the unsaturated fatty acid chains, intra- and intermolecular arrangements, cyclisation and 138 
fragmentation [13].These full-chain oxidised PLs along with chain fragmented PLs may 139 
initiate and modulate inflammatory reactions and have been implicated in the pathogenesis 140 
of age-related diseases [14, 15]. OxPLs act as lipid mediators of cellular and immune 141 
signaling via Toll like receptors (TLR) and are potential biomarkers of disease pathogenesis 142 
[14, 16]. Phosphocholine (PC) species with sn-2 palmitoyl or stearoyl moieties comprising; 1-143 
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palmitoyl-2-arachidonyl-sn-glycero-3-phosphorylcholine (PAPC), 1-palmitoyl-2-linoleoyl-sn-144 
glycero-3-phosphocholine (PLPC) 1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine 145 
(SAPC) and 1-stearoyl-2-linoleoylphosphatidylcholine (SLPC) were shown to generate several 146 
discrete oxidised phospholipids under different conditions [14, 17]. The oxidised 147 
phosphocholines (oxPCs) generated have immunogenic activity and act as ligands for 148 
scavenger receptors [17]. Oxidised metabolites are rapidly removed in plasma by cellular 149 
uptake and detoxified through catabolic activity in the liver [13].  150 
Our understanding of oxPCs, including their concentration in biological fluids, cells and 151 
tissues, is emerging with the aid of quantitative lipidomics. It is important to establish 152 
reliable and simplified mass spectrometry methods to analyse oxPCs [18]. However, the 153 
major challenge in quantitative oxidative lipidomics is the availability of authentic and 154 
deuterated standards for the lipids of interest [13, 19]. To mitigate this limitation, we have 155 
prepared additional oxidised products of PAPC, PLPC, SAPC and SLPC using Fenton reaction 156 
chemistry to expand the panel of oxPCs. 157 
In this paper we describe a mass spectrometry based multiple reaction monitoring (MRM) 158 
method that enables measurement of an extensive panel of oxPCs to investigate the plasma 159 
oxPC profiles of patients with CKD and CKD with co-morbid periodontitis compared to 160 
healthy controls. Using this method, we investigated the hypothesis that CKD and CKD co-161 
morbid with periodontitis have altered oxPC profiles in plasma compared to healthy 162 
controls.  163 
2. Materials and methods 164 
2.1 Chemicals 165 
Authentic lipid standards comprising: 1-palmitoyl-2-(5'-oxo-valeroyl)-sn-glycero-3-166 
phosphocholine (POVPC); 1-palmitoyl-2-(9'-oxo-nonanoyl)-sn-glycero-3-phosphocholine 167 
(PONPC); - 1-palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine (PGPC); 1-palmitoyl-2-168 
azelaoyl-sn-glycero-3-phosphocholine (PAzPC), 1-stearoyl-2-arachidonoyl-sn-glycero-3-169 
phosphocholine (SAPC) and 1-stearoyl-2-linoleoylphosphatidylcholine (SLPC) and one 170 
deuterated standard; 1, 2-dimyristoyl-sn-glycero-3-phosphocholine  1, 1, 2, 2-d4-N, N, N-171 
trimethyl-d9 (dDMPC), were purchased from Avanti Polar Lipids (Alabaster, USA). Solvents 172 
for lipid extraction and LC-MS of HPLC grade were purchased from Fisher Scientific, 173 
Loughborough, UK. All other chemicals were purchased form Sigma Aldrich (Dorset, UK), 174 
unless otherwise stated. 175 
2.2 In vitro oxidation of SAPC and SLPC and extraction of oxidised lipids 176 
SAPC and SLPC were oxidised with FeCl2 and H2O2 (Fenton reaction) according to the 177 
method described by Reis et al. [20]. Briefly, 100µg of phospholipids were oxidised with 178 
50mM H2O2 / 5mM FeCl2 in 1ml solution. The mixture was allowed to react at 37°C in the 179 
dark with sonication and occasional vortexing. Oxidation was monitored by electrospray 180 
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ionisation mass spectrometry at 24hrs and 48hrs. Products of lipid peroxidation resulted 181 
from cleavage of oxygen radicals producing short chain aldehydes, hydroxyaldehydes and 182 
dicarboxylic acids. Phospholipid oxidation products were extracted using the modified 183 
methyl tert butyl ether (MTBE) method with MTBE/methanol/water (10:3:2.5, v/v/v) 184 
containing 50µg/ml of BHT as we previously described [21].  185 
2.3 Plasma samples  186 
Plasma samples were from a randomly selected group of patients with CKD, and who were 187 
periodontally healthy (n=13) recruited to the Renal Impairment in Secondary Care (RIISC) 188 
study (Ethical approval for this cohort was covered by West Midlands South Birmingham 189 
NRES 10/H1207/6) [10]. The RIISC study is an ongoing, prospective cohort study 190 
investigating novel risk factors in the progression of CKD. Further plasma samples were 191 
collected from patients with CKD and with periodontitis as a comorbidity (n=20), patients 192 
with periodontitis without any self-reported illness (n=17), and without periodontitis or CKD 193 
(n=20) in the “INSPIRED TRIAL” (Influence of Successful Periodontal Intervention on Renal 194 
and Vascular Systems in patients with Chronic Kidney Disease-A Pilot Interventional 195 
Randomised Controlled Trial (INSPIRED). Ethical approval was by the National Research 196 
Ethics Service,  West Midlands - The Black Country, ref 15/WM/0006) [22]. The INSPIRED 197 
trial is an ongoing pilot randomised control trial investigating the effect of periodontal 198 
treatment on the cardio-renal health of patients with CKD. The patient demographics are 199 
shown in table 1. Blood samples were collected in the EDTA tubes and plasma was 200 
separated by centrifugation for 10 min at 3000×g at 4 °C within 2 hours of withdrawal and 201 
frozen at -80⁰C until further analysis. 202 
Inclusion criteria for all participants were: patients aged ≥18 years; able to provide consent 203 
to participate in the trial. Additional inclusion criteria for patients with CKD, for patients 204 
with CKD and periodontitis, and for systemically healthy patients with periodontitis are 205 
detailed as supplementary material. 206 
Exclusion criteria for all participants were: patients not meeting the inclusion criteria; or 207 
unable to provide informed consent. Additional exclusion criteria for patients with CKD, for 208 
systemically healthy patients with periodontitis, and for systemically healthy patients 209 
without periodontitis are detailed as supplementary material. 210 
For the purposes of this study, periodontitis is defined as those with a cumulative probing 211 
depth ≥30 mm. This is the sum of the deepest probing pocket per tooth, excluding probing 212 
depths <5 mm. This represents generalised moderate-severe periodontitis (periodontal 213 
health=1).  214 




Lipids were extracted from 10µl of individual plasma samples spiked with 200ng of dDMPC 217 
internal standard by MTBE method as previously reported [21]. The dried lipid extracts were 218 
reconstituted in 200µl methanol immediately prior to injection. Lipid extracts (10µl in 100% 219 
methanol) were injected for separation and analysis by LC-MS/MS.  220 
2.5 Phospholipid quantification  221 
For the purpose of phospholipid assay, lipids were extracted from 10 µl of plasma by the 222 
Folch protocol [23]. Phospholipid content of lipid extracts was quantified by 223 
spectrophotometry measurement of inorganic phosphorous (λ=797 nm) using a 224 
micromethod adapted from Rouser et al. [24], as described before [25].  225 
2.6 Liquid chromatography-mass spectrometry (LC-MS/MS) analysis of lipids 226 
Our previously described MRM-MS method [21] was adapted using the triple quadrupole 227 
mass spectrometer (QTRAP 5500, AB Sciex UK Ltd. Warrington) equipped with a standard-228 
ESI source, operated in a positive ion mode with an ionisation voltage of 5kV, entrance 229 
potential of 10 V, and ion source temperature of 400 °C, collision gas nitrogen 20V and ion 230 
source gas 25V. For optimisation of ESI and MS parameters, standard mixtures containing 231 
1ng/µl of each oxPC species was infused directly to the ESI source through an integrated 232 
syringe pump (Harvard apparatus) with a flow rate of 20µl/min. Lipid extracts were 233 
separated on a Luna Omega C18 column (internal diameter 2.1mm, column length 50mm, 234 
particle size 3µm, Phenomenex, Macclesfield, Cheshire, UK) with column guard installed. 235 
Mobile phases consisted of (A) 10 mM ammonium formate in methanol: water: formic acid 236 
(20:80:0.1, v/v/v) and (B) 2 mM ammonium formate in 2-propanol: methanol: formic acid 237 
(90:10:0.1, v/v/v) at 60 °C. Flow rate was maintained at 200 µl/min with the gradient as 238 
follows: 30% B from 0 to 1 min, 30–100% B from 1 to 6 min, 100% B 6–13min, 100–30% B 239 
from 13 to 14 min, 30% B 14–24 min. Analytical samples (10µl) were injected by the 240 
autosampler at 10⁰C with a constant flow of 200µl/min. Measurement and data analyses 241 
were performed in triplicate using Analyst software (version 1.6.2). Peak area of ions (m/z 242 
value) generating the PC-specific fragment at m/z 184, Peak area of the PC-specific fragment 243 
ion (m/z 184) which corresponds to the cleaved phosphocholine polar head was used for 244 
the quantification of oxPCs. The peak areas were normalised to the deuterated internal 245 
standard, dDMPC for each sample. Analyte concentrations in each sample were calculated 246 
using standard curves against PGPC (10-2000pg/µL), PONPC (10-1000pg/µL), PAzPC (10-247 
1000pg/µL) and POVPC (10-500pg/µL).  248 
2.7 Determination of linear dynamic range, limit of detection/quantification of OxPCs 249 
The method developed was for relative quantification, however, we prepared an external 250 
calibration using authentic standards (POVPC, PGPC, PONPC and PAzPC) to determine their 251 
linear range, lower limit of detection (LOD) and lower limit of quantification (LOQ). 252 
Calibration curves were produced by injecting 6 authentic solutions between 10-2000pg/µl 253 
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(10, 50, 100, 500, 1000, 2000pg/µl). The concentration ranges selected for the calibration 254 
curves were based on preliminary data on the dynamic ranges. LOD and LOQ were 255 
calculated using the blank determination method (n=20) from the International Conference 256 
on Harmonisation (ICH) guidelines as described previously [26]. LOD and LOQ are expressed 257 
as the analyte concentration corresponding to the sample blank value plus three and ten 258 
standard deviations, respectively. 259 
2.8 Evaluation of method reproducibility with intra-day and inter-day assays 260 
Quality control (QC) plasma samples (n=3) were analysed to evaluate the performance of 261 
the MS response over time, namely sensitivity of the method and reproducibility. Intra-day 262 
reproducibility was obtained from six analyses run consecutively while inter-day 263 
reproducibility was obtained from ten analyses run on different days over 1 month.  264 
2.9 Estimation of precision, accuracy, recovery and matrix effect for MRM method 265 
The method recommended by Matuszewski et al. [27] was adapted for recovery and matrix 266 
effect analysis. The recovery percentages were estimated by comparing the peak areas of 267 
four concentrations (100-1000pg/ml) of POVPC, PONPC, PGPC and PAzPC standards injected 268 
in methanol to the same phosphocholine standards spiked and extracted from plasma. The 269 
accuracy of the assay was determined by six replicates of QC samples at four concentrations 270 
during a single analytical run as described by Partani et al.,[28].   271 
2.10 Statistical analysis 272 
Multivariable regression models were constructed with measures of oxidative stress as 273 
dependent variables and clinical health parameters (healthy/ periodontitis only/ CKD only/ 274 
CKD and periodontitis), age and gender sex (male/female), smoking status (current smoker, 275 
ex-smoker, never smoker) and diabetes status (yes/no) as independent variables. All 276 
analyses were carried out using Stata/IC version 15.1 (StataCorp LLC). Significance was 277 














3.  Results 290 
3.1 Optimisation of LC-MS/MS identification of OxPC panel 291 
Four commercially available oxidised phospholipid standards, two native lipid standards 292 
oxidised through Fenton chemistry and one deuterated standard were employed to develop 293 
this targeted LC-MS/MS method. First, each commercially available standard was 294 
individually injected to identify optimal fragments based on their abundance for MRM 295 
analysis. The precursor ion scans were performed between 100 m/z to 1000 m/z mass range 296 
with ESI-MS in a positive ion mode. The At least three diagnostic product ion, 184 m/z was 297 
selected for each analyte, and collision energy, depolarisation potential and exit potential 298 
was optimised for each transition pair (Table 2). The product ion spectra of [MH]
+
 ions for 299 
POVPC, PGPC, PONPC and PAzPC standards showed an abundant product ion at m/z 184, 300 
which corresponds to the polar head group of phosphocholines ([H2PO4(CH2)2N(CH3)3]
+
).  301 
Next, MRM parameters were optimised to detect commercially available non-oxidised 302 
lipids; PAPC, PLPC, SAPC and SLPC (Figure 1).  To overcome the lack of standards for the 303 
identification of oxidised phospholipids, we generated a panel of oxidation products using 304 
PAPC, PLPC, SAPC and SLPC through the Fenton reaction between H2O2 and FeCl2 as 305 
previously described [20]. A range of oxidised phosphocholine species originating from PAPC 306 
(m/z 782.7), PLPC (m/z 758.7), SAPC (m/z 810.6) and SLPC (m/z 786.6) was monitored in a 307 
precursor ion scan for the phospholipid head group, m/z 184. Aligning with previous studies 308 
[14], chain-shortened, oxidised forms of SAPC were identified as 1-steroyl-2-(5'-oxo-309 
valeroyl)-sn-glycero-3-phosphocholine; SOVPC (m/z 622), 1-steroyl-2-glutaryl-sn-glycero-3-310 
phosphocholine; SGPC (m/z 638). Chain-fragmented oxidised SLPC ions were identified as 1-311 
steroyl-2-(9'-oxo-nonanoyl)-sn-glycero-3-phosphocholine; SONPC (m/z 678), 1-steroyl-2-312 
azelaoyl-sn-glycero-3-phosphocholine; SAzPC (m/z 694). Oxidised ions of PAPC were 313 
identified as 1-palmitoyl-2-(5-hydroxy-8-oxo-6-octenoyl)-sn-glycero-3-phosphocholine); 314 
HOOA-PC (m/z 648) and 1-palmitoyl-2-(5-keto-8-oxo-6-octenoic acid)-sn-glycero-3-315 
phosphocholine; KOOA-PC (m/z 648).  Chain-fragmented oxidised PLPC ions were identified 316 
as 1-palmitoyl-2-(4-keto-dodec-3-enadioyl)-sn-glycero-3-phosphocholine; KDdiA-PPC (m/z 317 
720), and 1-palmitoyl-2-(9-hydroxy-11-carboxy-undec-6-enoyl)-sn-glycero-3-318 
phosphocholine; HDdiA-PC (m/z 722) (Supplementary Figure 1 and Supplementary table 1). 319 
All oxidized lipids were separated from non-oxidized lipids by reverse-phase column 320 




3.2 Linear dynamic range, Intra-day and inter-day analyses of MRM-MS method for OxPCs 323 
To estimate the sensitivity of the method, we estimated the linearity, LOD and LOQ of the 324 
four commercially available OxPCs. The LOD and LOQ of the standard solutions were in the 325 
range 0.25 - 16pg and 0.5 – 37pg respectively with all correlation coefficients greater than 326 
0.99 (Supplementary table 2). Intra-day analyses were six consecutive analyses on the same 327 
day of QC plasma sample while the inter-day analyses were ten non-consecutive analyses 328 
over one month of the QC sample. The QC results show that the LC method is precise and 329 
reproducible with an intra-day assay %CV of 4-8 and the inter-day %CV of 6-14. 330 
(Supplementary table 3) 331 
 332 
 333 
3.3 Percentage recovery, matrix effect and accuracy of oxPCs standards  334 
Supplementary table 4 shows the average and the CV of oxPC recovery with and without 335 
matrix; percentages are in the range 73-91% and 90-99% respectively with CVs <15%.  The 336 
accuracy was also 97-102%. The precision and accuracy values were satisfactory. Precision is 337 
required to be within ±15% and accuracy between 85- 115% [24]. 338 
 339 
3.4 Analysis of plasma phospholipids and oxidised phosphocholines in CKD patients with 340 
or without periodontitis. 341 
Plasma phospholipids were analysed for phospholipid as described. Total phospholipid 342 
concentration in plasma was not different between healthy and disease groups (Figure 3). 343 
The patient demographics are described in Table 1. The distribution of patients and healthy 344 
controls were not different for weight but significant changes were observed for body mass 345 
index (BMI), age and sex distribution between groups. The percentage of smokers were not 346 
significantly different between groups but there was a significant difference observed for 347 
ex-smokers between healthy and disease groups. The co-morbidity of diabetes was also high 348 
in patients with CKD. To account for these differences, multivariable regression models were 349 
constructed with measures of oxidative stress as dependent variables and clinical health 350 
parameters (healthy/ periodontitis only/ CKD only/ CKD and periodontitis), BMI, age, sex, 351 
smoking status and diabetes as independent variables. Significance was accepted as p<0.05.   352 
Individual estimates of specific OxPC showed significant differences (Figure 4 and Table 3) 353 
between healthy and disease groups. Compared to healthy subjects, patients with 354 
periodontitis, CKD and with both diseases had significantly higher levels of HDdiA-PC 355 
(P<0.005; Figure 4L). SAzPC levels were significantly higher only in CKD group compared to 356 
healthy subjects (P=0.001; Figure 4H). In periodontitis; POVPC (P=0.016; Figure 4A), PONPC 357 
(P=0.029; Figure 4C) and SOVPC (P=0.043; Figure 4E) were significantly higher compared to 358 
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the healthy group and KOOA-PC was significantly higher in patients with both diseases than 359 
in healthy controls (P<0.001; Figure 4J).  360 
Conversely, some oxPCs were found be significantly lower in CKD plasmas; SGPC (P=0.026; 361 
Figure 4F), and in the presence of both diseases; PAzPC (P=0.047; Figure 4D).  362 
4. Discussion  363 
This study has focused on developing a method to simultaneously quantify, with high 364 
sensitivity, a panel of 12 oxPCs in biological fluids and applying the method to plasma 365 
samples from patients with CKD and chronic periodontitis as a comorbidity for the first time. 366 
We optimised chromatography conditions and included in-house oxidised lipid standards to 367 
cover a panel of oxPCs.  With the use of the Lunar Omega polar C18 column (Phenomenex, 368 
UK), this method achieved high selectivity for polar oxidised phosphocholine lipids without 369 
diminishing important non-polar interactions. By combining column characteristics with the 370 
solvent system, the current method decreased the retention time of the analytes from 44 371 
minutes to 24 minutes compared to our previously published method [21].  372 
We and others have shown the presence of systemic inflammatory burden in periodontitis, 373 
induced by periodontal bacteraemia activating peripheral blood neutrophils to release ROS 374 
(6). Thus, a measure of periodontitis that captures this infectious-inflammatory exposure is 375 
required. The measure used, cumulative probing depth, can be readily calculated from 376 
routinely collected periodontal measurements and approximates the extent of the 377 
periodontal wound. It can be used to differentiate measures of previous disease experience, 378 
such as recession and clinical attachment loss, which may not influence the patient’s current 379 
systemic health. The current, commonly used case definitions of periodontitis may not be 380 
able to achieve this, as has been reported by other researchers [29, 30]. Cumulative probing 381 
depth also accounts for tooth loss in a way that other measures, such as mean probing 382 
pocket depth (PPD), do not.    383 
Dyslipidaemia and disturbances in lipid metabolism are reported previously in patients with 384 
CKD who are pre-dialysis and who are receiving long-term renal replacement therapy with 385 
haemodialysis [31, 32].  Many other studies have investigated the lipid parameters including 386 
total cholesterol, high density lipoprotein cholesterol (HDL-C), Low density cholesterol (LDL-387 
C), and triglycerides in CKD. These studies indicated that dyslipidemia can increase the risk 388 
of atherosclerotic cardiovascular diseases in patients with CKD [32, 33].  We have previously 389 
demonstrated that dyslipidaemia is associated with oxidative stress in diabetes patients 390 
with periodontitis, relative to people with diabetes alone [34]. We have also shown the 391 
damaging effects of oxidised lipids ( from oxLDL) including oxidised cholesterol (27-392 
hydroxycholesterol), using an in vitro neuronal cell culture system [35] and on endothelial 393 
cells [36].  394 
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Plasma lipoproteins carry hydrophobic and water insoluble lipids to be delivered to tissue 395 
and cells. Phospholipids residing at the surface layer of lipoproteins constituting ∼20–25% 396 
of the particle by weight [37] are primary targets of oxidative damage with formation of 397 
oxidised phospholipids. Primary oxidation products generated from the most abundant 398 
molecular species of PCs (PAPC, SLPC, PLPC and SAPC) are present in LDL [38, 39]. Reis et al., 399 
previously compared the molecular lipidomic profile of LDL in patients with non-diabetic, 400 
advanced renal disease to that of age-matched controls [40]. The study indicated 401 
significantly lower levels concentrations of PCs in LDL particles. A study conducted by Yang 402 
et al., described changes to the urinary phospholipid profile in CKD patients [41]. 403 
Collectively, this work suggested an important link between phospholipid profiles and CKD.  404 
Based on these measures, we sought to investigate whether increased oxidative stress may 405 
have contributed to differences in the circulating profile of phosphocholines in patients with 406 
CKD with or without periodontitis. Elevated peripheral oxidative stress has been reported in 407 
periodontitis, arising from peripheral blood neutrophil activation by periodontal 408 
bacteraemia, including extracellular release of reactive oxygen species [42]. While the 409 
damage to macromolecules, including phospholipids are inevitable, so far none of the 410 
studies have investigated oxidised phospholipid profiles in periodontitis. To our knowledge, 411 
this is the first time fragmented oxPCs have been analysed in the plasma of patients with 412 
CKD with periodontitis as a comorbid inflammatory disease.  This paper has focused on the 413 
oxidative modification to PAPC, PLPC, SAPC and SLPC classes of lipids.  414 
HDdiA-PC levels were significantly increased in all patient groups tested and the keto acid 415 
analogue, KOOA-PC was significantly higher in the presence of periodontitis or comorbid 416 
with CKD. These oxPCs share a common structural moiety possessing sn-2 esterified γ-417 
hydroxy (or oxo)-α,β unsaturated carbonyl-containing fatty acids. This suggests that they 418 
represent limited oxidation before chain fragmentation to form shorter fatty acid moieties, 419 
which may relate to the concentration or nature of radical species involved in oxidation. 420 
Eugene et al., described the generation of this family of truncated PCs using unilamellar 421 
vesicles in the presence of the myeloperoxidase (MPO)-H2O2-NO2
-
 system [43].  MPO is most 422 
abundantly expressed in neutrophil granules and released either into the phagosome or the 423 
extracellular space where it catalyses the conversion of H2O2 and chloride in to 424 
hypochlorous acid. Therefore, it is possible that neutrophil hyperactivity in chronic 425 
periodontitis [42, 44] has a key role in generating this family of PCs.   426 
PCs with an acyl chain at the sn-2 position are known to have high affinity for the 427 
macrophage scavenger receptor, CD36 [45]. Chain fragmented oxPCs, such as POVPC, were 428 
less effective in binding to the CD36 receptor.  Moreover, altering the sn-2 esterified group 429 
by repositioning of the γ –hydroxy moiety by one methylene group or completely losing γ –430 
hydroxyl moiety significantly reduced CD36 binding ability. The work by Eugene et al. 431 
highlighted the highly conserved nature of the critical structural elements required for 432 
oxidised phospholipids to serve as ligands for CD36 and uptake by macrophages [46]. It is 433 
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established that LDL loaded macrophages can lead to exacerbation of inflammation and 434 
involvement in cardiovascular disease pathologies via foam cell formation. The altered oxPC 435 
profile observed here may contribute to increased risk for CVD, as observed in patients 436 
comorbid for CKD and periodontitis, due to altered clearance by CD36 and binding to pro-437 
inflammatory TLRs [16]. 438 
The biological activity of circulating oxPCs is extensive and has been reviewed previously 439 
[13, 17]. Using an in vitro approach, Gargalovic et al., have shown that oxPCs at non-toxic 440 
concentrations (50 μg/ml) can regulate >1000 genes in endothelial cells [47]. OxPAPC 441 
disrupts endothelial barrier properties and activates both pro- and anti-inflammatory 442 
pathways [48]. OxPAPC altered endothelial transcriptome analysis revealed the complexity 443 
of various regulatory pathways [48].  Using a systems level network approach, Hitzel et al., 444 
described oxPC regulated amino acid metabolism in endothelial cells [49]. They further 445 
demonstrated that oxPAPC induces a gene network regulating serine-glycine metabolism 446 
with the mitochondrial methylenetetrahydrofolate dehydrogenase/cyclohydrolase 447 
(MTHFD2), which is active in atherosclerotic plaque material with implications in for 448 
cardiovascular disease.  449 
Taken together, this work highlights the importance of accurate measurement of oxPCs 450 
within biological fluids and possible implications of disease comorbidities on 451 
phosphocholine profile.   452 
 453 
5. Conclusion  454 
We have developed a quantitative oxPC lipidomic method for application in plasma analysis. 455 
This sensitive, accurate and improved method is able to detect differences between healthy 456 
people and patients with oxidative stress related diseases. The signature of OxPC found in 457 
our study of CKD, with or without periodontal comorbidity, discriminated between the two 458 
conditions. This study has potential to help understand any role of oxPCs in the 459 
complications of CKD and indicates their potential use as biomarkers for diagnosis, 460 
prognosis and treatment. 461 
 462 
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Figure 1: Chromatographic separation of native PAPC, SAPC, PLPC and SLPC standards. 621 
Native PAPC, SAPC, PLPC and SLPC in a positive ion mode revealed single chromatographic 622 
peaks that corresponded to the protonated molecule at m/z 782.7, m/z 810.6, m/z 758.7 623 
and m/z 786.6 respectively; with their respective spectra in the inserts. Ions observed in LC-624 
MS spectra at m/z 804.7, m/z 832.6, m/z780.7 and m/z 808.6 corresponded to sodiated 625 
adducts ([MNa]
 +






Figure 2: Extracted ion chromatograms (XIC) of individual molecular species of four 630 
commercial synthetic standards and eight chain fragmented oxPCs. MRM method developed 631 
for 12 oxPCs, which consist of four commercially available standards (POVPC, PONPC, PGPC, 632 
PAzPC) and eight iron oxidised products of SAPC and SLPC lipids; namely SOVPC (1-stearoyl-633 
2-(5'-oxo-valeroyl)-sn-glycero-3-phosphocholine), SGPC (1-stearoyl-2-glutaryl-sn-glycero-3-634 
phosphocholine), SONPC (1-stearoyl -2-(9'-oxo-nonanoyl)-sn-glycero-3-phosphocholine) 635 
SAzPC (1-stearoyl-2-azelaoyl-sn-glycero-3-phosphocholine), HOOA-PC (1-palmitoyl-2-(5-636 
hydroxy-8-oxo-6-octenoyl)-sn-glycero-3-phosphocholine), KOOA-PC (1-palmitoyl-2-(5-637 
hydroxy-8-oxo-6-octenoic acid)-sn-glycero-3-phosphocholine), KDdiA-PPC (1-palmitoyl-2-(4-638 
keto-dodec-3-enadioyl)-sn-glycero-3-phosphocholine, and HDdiA-PC (1-palmitoyl-2-(9-639 





































Figure 3: Total phospholipid content in disease groups. 645 






Figure 4. OxPC concentrations (µmol/L plasma ± SEM) measured in plasma from healthy 648 
control, patients with periodontitis, patients with CKD and patients with CKD comorbid 649 
with periodontitis.  650 
Tables 651 
 Table 1: Demographics of patients and healthy control individuals. Data presented is mean 652 
(SD) unless otherwise stated 653 
 654 
 655 
Table 2: Selected multiple MRM parameters (Q1/Q3 transition pair, declustering potential 656 







DP (V) CE (V) CXP (V) 
Retention 
time (min) 












Weight (Kg) 74 ( 17) 78 (19) 79 (15) 87 (23) 
No 
BMI (Kg/m2) 25 (4) 29 (6) 27 (4)  31 (8) 
Yes 












5 10 12 10 
No 
Ex-smokers (%) 10 65 59 30 
Yes 




PGPC 610.0/184.0 100 10 37 26 7.71 
PONPC 650.0/184.0 100 10 39 14 8.24 
PAzPC 666.0/184.0 100 10 37 16 8.02 
SOVPC 622.0/184.0 100 26 45 18 8.23 
SGPC 638.0/184.0 100 16 35 10 8.18 
SONPC 678.0/184.0 100 16 43 18 8.97 
SAzPC 694.0/184.0 100 21 37 24 8.58 
HOOA-PC 649.0/184.0 100 31 41 10 8.30 
KOOA-PC 648.0/184.0 100 26 41 24 8.35 
KDdiA-PC 720.0/184.0 100 6.0 45 16 8.67 
HDdiA-PC 722.0/184.0 100 21 37 28 8.65 
DMPC (d13) 691.0/481.0 100 96 38 12 9.53 
 659 
Table 3: Multivariable regression analysis of oxPCs between disease groups. Groups were 660 
analysed with measures of oxidative stress as dependent variables and clinical health 661 
parameters (healthy/ periodontitis only/ CKD only/ CKD and periodontitis), age and sex as 662 









































































Perio      
vs Healthy     
0.016 0.043 0.083 0.029 0.526 0.052 0.096 0.331 0.005 0.848 0.238 0.372 
CKD      
vs Healthy     
0.653 0.376 0.577 0.104 0.195 0.162 0.909 0.026 0.000 0.112 0.001 0.266 
CKD+Perio 
vs Healthy     
0.760 0.788 0.946 0.864 0.061 0.000 0.969 0.065 0.000 0.047 0.595 0.051 
CKD       
vs Perio         
0.010 0.006 0.445 0.851 0.281 0.932 0.109 0.001 0.003 0.034 0.002 0.529 
CKD+Perio 
vs Perio         
0.049 0.025 0.091 0.027 0.106 0.000 0.095 0.003 0.009 0.013 0.623 0.152 
CKD+Perio 
vs CKD           
0.240 0.307 0.335 0.006 0.618 0.000 0.895 0.250 0.604 0.889 0.000 0.402 
Highlights: 
• We describe a targeted mass spectrometry method to simultaneously quantify an expanded 
panel of 12 oxidised phosphocholines in plasma.   
• This method reproducibly and sensitively quantified oxidised phosphocholines in the 
individuals with chronic kidney disease and with periodontitis as a co-morbidity. 
• Patients with chronic kidney disease and periodontitis as a co-morbidity, have altered 
oxidised phosphocholine profiles in plasma compared to healthy controls. 
